

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

NCT07369024

Status	RECRUITING
Phase	Phase 2
Sponsor	Mohsen Saidinejad
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (6)

- Between the ages 5-20 years
- Diagnosed sickle cell disease. Homozygous (HbSS) or heterozygous (HbSC, HbSBetaThal Plus or Zero) will be included.
- Presenting with VOE pain, requiring IV pain medication.
- First dose of analgesic medication is given before patient approached for participation in the study.
- Primary language is English or Spanish

... and 1 more (see full listing online)

Exclusion (17)

- Sickle cell trait only
- Patients whose primary language is other than English or Spanish
- Pain attributed to causes other than VOE
- Not requiring IV for pain treatment
- No analgesic (e.g. opiate) is given before approach for study participation due to any reason, including problem with IV access.

... and 12 more (see full listing online)

Locations (1 total)

Harbor UCLA Medical Center, Torrance, California, United States